Multicenter phase 1/2 study of forodesine in patients with relapsed peripheral T cell lymphoma.

MLA

Maruyama, Dai, et al. “Multicenter Phase 1/2 Study of Forodesine in Patients with Relapsed Peripheral T Cell Lymphoma.” Annals of Hematology, vol. 98, no. 1, Jan. 2019, pp. 131–42. EBSCOhost, https://doi.org/10.1007/s00277-018-3418-2.

APA

Maruyama, D., Tobinai, K., Ando, K., Yoshida, I., Hidaka, M., Murayama, T., Okitsu, Y., Tsukamoto, N., Taniwaki, M., Suzumiya, J., Tamura, K., Yamauchi, T., Tsukasaki, K., Ueda, R., Uchida, T., Maeda, Y., Shibayama, H., Nagai, H., Kurosawa, M., & Suehiro, Y. (2019). Multicenter phase 1/2 study of forodesine in patients with relapsed peripheral T cell lymphoma. Annals of Hematology, 98(1), 131–142. https://doi.org/10.1007/s00277-018-3418-2

Chicago

Maruyama, Dai, Kensei Tobinai, Kiyoshi Ando, Isao Yoshida, Michihiro Hidaka, Tohru Murayama, Yoko Okitsu, et al. 2019. “Multicenter Phase 1/2 Study of Forodesine in Patients with Relapsed Peripheral T Cell Lymphoma.” Annals of Hematology 98 (1): 131–42. doi:10.1007/s00277-018-3418-2.